AI algorithm can help identify high-risk heart patients: Study
New Delhi: A team of US researchers, studying a type of heart disease known as hypertrophic cardiomyopathy (HCM) said they have calibrated an artificial intelligence (AI) algorithm to quickly and more specifically identify patients with the condition and flag them as high risk for greater attention during doctor's appointments.
The algorithm, known as Viz HCM, had previously been approved by the Food and Drug Administration (FDA) for the detection of HCM on an electrocardiogram (ECG).
The Mount Sinai study, published in the journal NEJM AI, assigns numeric probabilities to the algorithm's findings.
For example, while the algorithm might previously have said 'flagged as suspected HCM' or 'high risk of HCM,' the Mount Sinai study allows for interpretations such as, 'You have about a 60 percent chance of having HCM,' said Joshua Lampert, Director of Machine Learning at Mount Sinai Fuster Heart Hospital.
As a result, patients who had not previously been diagnosed with HCM may be able to get a better understanding of their individual disease risk, leading to a faster and more individualized evaluation, along with treatment to potentially prevent complications such as sudden cardiac death, especially in young patients.
'This is an important step forward in translating novel deep-learning algorithms into clinical practice by providing clinicians and patients with more meaningful information.
Clinicians can improve their clinical workflows by ensuring the highest-risk patients are identified at the top of their clinical work list using a sorting tool,' said Lampert, Assistant Professor of Medicine (Cardiology, and Data-Driven and Digital Medicine) at the Icahn School of Medicine at Mount Sinai.
HCM impacts one in 200 people worldwide and is a leading reason for heart transplantation.
However, many patients don't know they have the condition until they have symptoms and the disease may already be advanced.
'This study reflects pragmatic implementation science at its best, demonstrating how we can responsibly and thoughtfully integrate advanced AI tools into real-world clinical workflows,' said co-senior author Girish N Nadkarni, Chair of the Windreich Department of Artificial Intelligence and Human Health and Director of the Hasso Plattner Institute for Digital Health.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
10 hours ago
- The Hindu
After 18-year battle with genetic heart disease, 41-year-old Bengaluru resident gets transplant
For 18 long years, life for a 41-year-old Bengaluru resident was a battle against a failing heart. Diagnosed with a genetically inherited cardiomyopathy in his early twenties, his struggle of nearly two decades ended with a life-saving heart transplant at a private hospital in the city. A marketing manager by profession, Mohammed Rafi — who hails from Kerala — was diagnosed with Hypertrophic Cardiomyopathy (HCM) at the age of 23, a disease that has been running in his family for ages. From then on, his life took an unexpected turn from being unable to go to gym and or play in cricket tournaments to a daily battle for survival. Runs in family His mother, sister, grandmother, uncle, cousin, and even his young daughter had the same condition. However, it was not until his daughter passed away, at the age of four, that they began to explore the genetic factor. Doctors at Manipal Hospital Old Airport Road, where the transplant was done, said the patient, who otherwise led an active life, experienced unusual fatigue while playing cricket during an office excursion. However, he ignored it to be a normal consequence of skipping breakfast. Other symptoms of dizziness, breathlessness, and bloating persisted for days. Worried about this sudden change in his health, he visited a doctor in Kerala, only to discover that he was in the early stages of HCM — a serious, often hereditary condition where the heart muscle becomes abnormally thick. Although he continued to lead a normal life, the physical toll began to affect his professional and personal life over time. 'Because my job included business travel to different places, I had to ask people to help push my bike through traffic. At one point, I realised I could not even lift my laptop,' he said. Initially treated by Sridhara G, Consultant - Interventional Cardiology and Cardiac Electrophysiology at Manipal Hospital Old Airport Road, for over a decade, he underwent the implantation of an AICD (Automated Implantable Cardioverter Defibrillator). While this intervention gave some relief for a couple of years, his health gradually worsened with symptoms, such as swelling in the body, constant fatigue, and reduced mobility. This was when he was diagnosed with heart failure, with a heart transplantation being the last resort. Wait for organ donors The waiting period for a heart transplant was lengthy, with a severe shortage of compatible organ donors. Registered on the transplant list since 2019, it was only three months ago that he finally underwent the transplant, on March 21, 2025. A team of doctors led by Devananda N.S., HOD and Consultant – Cardiothoracic Vascular Surgery, and Heart and Lung Transplant Surgery, conducted the surgery. After two weeks of hospital stay, he was discharged on April 5, 2025. His recovery process is still ongoing, with doctors anticipating another 3-4 months for full recovery. 'If families like Mr. Rafi's are screened early, disease modification to some extent is possible, and other asymptomatic members of the family can also be helped. This is high time we work on creating a national genetic database on such rare cardiac disorders,' said Dr. Devananda.
Mint
11 hours ago
- Mint
Hair loss isn't just a man's problem. Four ways to treat female baldness.
As a professional dancer on Broadway, Lindsey Cornman was known for her curly, strawberry-blonde hair along with her high kicks and pirouettes. When balls of her hair started falling in the shower, it eroded her self-confidence. She ended up getting divorced, though hair loss wasn't the primary reason. 'It didn't help to not feel good about myself," says Cornman, now 42 years old. Fifty-five percent of women deal with hair loss by the age of 70, dermatologists at Rutgers New Jersey Medical School and Marconi University found. The most common condition is female-pattern hair loss, which is genetic, affecting 30 million women in the U.S. By comparison, more than 80% of men experience hair loss and 50 million men have male-pattern hair loss, found NYU Langone Health and the National Institutes of Health, respectively. 'I see more women with concerns about hair loss than men," says Dr. Christina Weng, dermatologist at Massachusetts General Hospital and chief medical officer at Pelage Pharmaceuticals. She says treatment options can be divided into four categories: medicine, therapy, nutritional supplements, and lifestyle changes. 'The best treatment is the one they are going to stick with, because they aren't overnight fixes, and they won't see results for at least six months." What does the female-pattern hair loss look like? It usually shows up as the widening of the part line at the top of the head, and thinning all over the scalp, explains Dr. Weng. The silver lining: The hair line at the front of the scalp usually stays the same for women, contrary to men with receding hair lines. Here are the treatment options: Medicine The most commonly prescribed drug is Minoxidil, the only FDA-approved treatment for hair loss. Dr. Weng says it works better for people who can convert an enzyme in the hair follicle to its active form—overall, only 30% of people respond to it. Another medicine is Spironolactone, which helps block the testosterone derivate DHT that contributes to genetic hair loss. It is especially effective if women have genetic hair loss coupled with hormonal issues or polycystic ovarian syndrome, Dr. Weng says, though it can cause lightheadedness. These drugs usually aren't covered by insurance. Therapy New hair loss therapies for women have come forward in the last decade. Some stimulate hair follicles with targeted laser light; others inject clients with platelet-rich plasma or stems cells to try to get hair to grow. Some of these treatments cost thousands of dollar, and most times aren't covered by insurance. You should get a blood test before trying any of them, Cornman's trichologist, William Gaunitz of Laguna Beach, Calif. says. (Trichologists specialize in treating diseases of the hair and scalp.) If women are deficient in iron or zinc, then trying to activate the building blocks for healthy hair growth can cause the follicles to become overstimulated and even lead to profuse shedding, he says. Nutritional Supplements Gaunitz says poor nutrition is a big factor in the 100,000-plus women he has treated. 'Women are more susceptible to accelerating genetic hair loss, because of fad diets," he says. Vitamin D3 deficiency is by far the largest cause, followed by deficiencies in Ferritin, which stores iron, and then in vitamin B12. Women going through menopause have the toughest hand dealt to them. Estrogen levels drop sharply, which means the body's natural hair protection hormone is close to off duty, Gaunitz explains. They may need to take nutritional supplements for vitamins D3 or B12, he says. One of the biggest misconceptions out there: Biotin supplements will give women beautiful locks. Not true, says Dr. Carolyn Goh, dermatologist and director of the Hair and Scalp Disorders Clinic at UCLA Health. Unless you are deficient in this vitamin, taking supplements won't help. Lifestyle Changes Stress is another contributor to female baldness. Lack of sleep affects the adrenal and thyroid glands, compounding the problem. Gaunitz tells his clients to avoid stress and sleep seven to eight hours a night. To find out the root cause of hair loss, hair loss tests can help. The Mayo Clinic suggests a scalp biopsy in which a doctor collects samples and examines them under a microscope, a light microscopy in which a doctor examines hairs on the head with a special instrument, or a blood test which uncovers medical reasons for hair loss. Women can also do a simple hair pull test at home. Gaunitz tells how to do it. Throughout the head, grip the hairs with your fingers and gently pull them back through the fingers. Do it twice. If you are left with four or more hairs in your hands on the first pull, it signifies 'something to think about;" if you get three or more hairs on the second pull, it's a more pressing problem. Cornman, the former dancer, took supplements to counter her low vitamin D3 level, added natural DHT blockers to the mix, and refreshed her hair care routine. She now has a full head of curly strawberry-blonde hair.
Time of India
a day ago
- Time of India
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies
Bengaluru: The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a safety program to protect patients from risky drugs, for currently approved CAR-T cell immunotherapies. REMS is required by the FDA to ensure a drug's benefits outweigh its risks by managing serious safety concerns. The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed warnings for cytokine release syndrome and neurological toxicities, and medication guides. The cancer therapies include Bristol-Myers Squibb's Breyanzi and its partnered therapy Abecma with 2seventy bio , Johnson & Johnson's unit Janssen and Legend Biotech's Carvykti, Novartis AG's Kymriah, and Gilead Sciences' unit Kite's Tecartus and Yescarta. Bristol-Myers Squibb and Gilead Sciences did not immediately respond to Reuters' requests for comment. These are gene therapies that are currently approved to treat blood cancers, such as multiple myeloma and certain types of leukemia and lymphoma, the health regulator said. CAR-T treatment generally involves extracting disease-fighting white blood cells known as T-cells from a patient, re-engineering them to attack cancer and infusing them back into the body. In January 2024, the FDA asked several drugmakers to add a serious warning on the label of their cancer therapies that use CAR-T technology after reports of T-cell malignancies and adverse events identified since approval. The FDA earlier said the risk of T-cell malignancies including leukemia and lymphoma applies to all therapies in the class and can lead to hospitalization and death.
